SCHEMBL5149545

SCHEMBL5149545

CCOc1cccc(C2SCC(=O)N2Cc2ccc(OC)cc2)c1

nearest known ligand 0.67

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.67
MEN1 O00255 3/20 0.67
ALDH1A1 P00352 2/20 0.62
PTGS1 P23219 1/20 0.55
PTGS2 P35354 1/20 0.55
KCNA5 P22460 4/20 0.53
POLB P06746 1/20 0.51
HCRTR1 O43613 1/20 0.51
HCRTR2 O43614 1/20 0.51
MAPT P10636 4/20 0.50
TDP1 Q9NUW8 3/20 0.50
KDM4E B2RXH2 1/20 0.50
GAA P10253 1/20 0.50
MAPK1 P28482 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5151519 0.92 KMT2A (0.74) KMT2AMEN1ALDH1A1PTGS1PTGS2
SCHEMBL5155040 0.87 PTGS1 (0.59) KMT2AMEN1ALDH1A1PTGS1PTGS2
SCHEMBL5152780 0.87 KMT2A (0.50) KMT2AMEN1ALDH1A1PTGS1PTGS2
SCHEMBL5149639 0.85 ACHE (0.51) KMT2AMEN1ALDH1A1POLBHCRTR1
SCHEMBL5149492 0.85 KMT2A (0.47) KMT2AMEN1ALDH1A1POLBHCRTR1
SCHEMBL5151512 0.85 HCRTR1 (0.68) KMT2AMEN1ALDH1A1PTGS1PTGS2
SCHEMBL745925 0.83 KMT2A (0.51) KMT2AMEN1ALDH1A1PTGS1PTGS2
SCHEMBL5149554 0.83 ACHE (0.45) KMT2AMEN1ALDH1A1POLBHCRTR1
SCHEMBL5152422 0.83 MGAM (0.58) KMT2AMEN1ALDH1A1POLBHCRTR1
SCHEMBL5152175 0.81 KMT2A (0.58) KMT2AMEN1ALDH1A1PTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7223754-B2 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2007-05-29 US disclosed
US-20070066597-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2007-03-22 US disclosed
US-20050148587-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2005-07-07 US disclosed
US-20050113421-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2005-05-26 US disclosed
WO-2004017965-A1 1,3-THIAZOLIN-4-ONES AS THERAPEUTIC COMPOUNDS IN THE TREATMENT OF PAIN IONIX PHARMACEUTICALS LIMITED (GB) 2004-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113421-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders TRPV2, RYR2, VDAC2 KMT2A 4084/4885MEN1 3532/4885ALDH1A1 3381/4885
US-20070066597-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders RYR2, CACNB2, CACNA1I KMT2A 3401/4885MEN1 3820/4885ALDH1A1 1370/4885
US-20050148587-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders RYR2, CACNB2, CACNA1I KMT2A 3401/4885MEN1 3820/4885ALDH1A1 1370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.